FIELD: medicine.
SUBSTANCE: aqueous pharmaceutical preparation contains therapeutically effective amount of Cetuximab or EMD 72000, or one of the appropriate murine, humanised or chimeric analogues of an antibody, a buffer of pH 5.2 to 6.0, amino acid chosen from the group containing L-arginin, glycine and L-methionine, and a surface-active substance chosen from the group containing polyethylene sorbitan fatty acid ester and polyoxyethylene-polyoxypropylene copolymer provided that it does not contain sugar.
EFFECT: offered aqueous preparation high temperatures, and can be used for treatment of tumours.
10 cl, 5 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| FREEZE-DRIED PREPARATION, ANTIBODY-CONTAINING AGAINST EGF RECEPTOR | 2002 |
|
RU2339402C2 |
| SOLID FORMS OF ANTI- EGFR ANTIBODIES | 2004 |
|
RU2397755C2 |
| HIGH-CONCENTRATION LIQUID ANTI-EGFR ANTIBODY COMPOSITIONS | 2005 |
|
RU2390353C2 |
| LYOPHILIZED IMMUNOCYTOKINE-CONTAINING PREPARATION | 2003 |
|
RU2316348C2 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
| CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| METHOD FOR THE PRODUCTION OF IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION | 2019 |
|
RU2742655C1 |
| LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION ANTIBODY | 2008 |
|
RU2497544C2 |
| LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION ANTIBODY | 2013 |
|
RU2701181C2 |
